Despite a growing emphasis on biomarkers in research into Alzheimer disease (AD) and Parkinson disease (PD), there is little consensus as to which biomarkers are most effective. In this Review, Lleó and colleagues discuss cerebrospinal fluid (CSF) biomarkers for AD and PD, with a particular emphasis on applicability to clinical trials. Compared with AD, less is known about CSF biomarkers in PD, and the authors highlight several areas for further research.
- Alberto Lleó
- Enrica Cavedo
- Brit Mollenhauer
